#### PATENT COOPERATION TREATY

From INTE	the RNATIONAL SEA	RCHING AUTHO	ORITY		REC'D 1 4 SEP 2005		
To:					PCT WIPO P		
	see form	PCT/ISA/220			TEN OPINION OF THE		
					NAL SEARCHING AUTHORITY PCT Rule 43 <i>bis</i> .1)		
	•			(day/month/year) see form PCT/ISA/210 (second sheet)			
	icant's or agent's file form PCT/ISA/2			FOR FURTHER ACTION See paragraph 2 below			
International application No. PCT/JP2005/011001			International filing date (	Priority date (day/month/year) 11.06.2004			
	national Patent Clas 3G9/097, C08G6		both national classification 3/685	and IPC			
	licant NON KABUSHIK	I KAISHA			·		
1.	This opinion contains indications relating to the following items:						
	☑ Box No. I	Basis of the op	pinlon				
	☐ Box No. II	Priority					
	Box No. III		-	ard to novelty, inventiv	e step and industrial applicability		
	LI Box No. IV	Lack of unity o					
	⊠ Box No. V	Reasoned stat applicability; ci	tement under Rule 43 <i>bi</i> s itations and explanation	s.1(a)(i) with regard to s supporting such stat	novelty, inventive step or industrial ement		
	⊠ Box No. VI	Certain docum	ents cited				
	⊠ Box No. VII		s in the international app				
	☐ Box No. VIII Certain observations on the international application						
2.	FÚRTHER ACT				•		
	written opinion o the applicant cho	f the Internation coses an Author reau under Rule	al Preliminary Examinin ity other than this one to	ig Authority ("IPEA"). F o be the IPEA and the	usually be considered to be a lowever, this does not apply where chosen IPEA has notifed the tional Searching Authority		
	If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of three months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.						
	For further option	ns, see Form PC	CT/ISA/220.				
З.	For further detail	ls, see notes to l	Form PCT/ISA/220.				

Name and mailing address of the ISA:

European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 Authorized Officer

Masson, P

Telephone No. +49 89 2399-2051



## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2005/011001

_	Box	k No.	I Pagin of the entition		
_					
1.	With regard to the language, this opinion has been established on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.				
			opinion has been established on the basis of a translation from the original language into the following uage , which is the language of a translation furnished for the purposes of international search ler Rules 12.3 and 23.1(b)).		
2.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this opinion has been established on the basis of:				
	a. type of material:				
	. [	Ιа	sequence listing		
		□ ta	able(s) related to the sequence listing		
	b. fo	b. format of material:			
		] in	written format		
		] in	computer readable form		
	c. tin	ne of	filing/furnishing:		
		] co	ontained in the international application as filed.		
		] file	ed together with the international application in computer readable form.		
		] fu	rnished subsequently to this Authority for the purposes of search.		
	_				
3.		copie	dition, in the case that more than one version or copy of a sequence listing and/or table relating thereto been filed or furnished, the required statements that the information in the subsequent or additional is is identical to that in the application as filed or does not go beyond the application as filed, as opriate, were furnished.		
1	Additional comments:				

## WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY

International application No. PCT/JP2005/011001

Box No. V Reasoned statement under Rule 43*bis*.1(a)(i) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-10

No: Claims

Inventive step (IS)

Yes: Claims

1-10

No: Claims

Industrial applicability (IA)

Yes: Claims

1-10

No: Claims

2. Citations and explanations

see separate sheet

#### Box No. VI Certain documents cited

 Certain published documents (Rules 43bis.1 and 70.10) and /or

2. Non-written disclosures (Rules 43bis.1 and 70.9)

see form 210

#### Box No. VII Certain defects in the International application

The following defects in the form or contents of the international application have been noted:

see separate sheet

#### Box No. VIII Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

#### Cf V:

Reference is made to the following documents:

- D1: EP-A-1 254 918 (CANON KABUSHIKI KAISHA) 6 November 2002 (2002-11-06)
- D2: EP-A-1 253 162 (CANON KABUSHIKI KAISHA) 30 October 2002 (2002-10-30)
- D3: EP-A-1 253 161 (CANON KABUSHIKI KAISHA) 30 October 2002 (2002-10-30)
- D4: EP-A-1 236 755 (CANON KABUSHIKI KAISHA) 4 September 2002 (2002-09-04)
- D5: EP-A-1 336 635 (CANON KABUSHIKI KAISHA) 20 August 2003 (2003-08-20)
- D6: EP-A-1 245 605 (CANON KABUSHIKI KAISHA) 2 October 2002 (2002-10-02)
- D7: WO 2004/038512 A (CANON KABUSHIKI KAISHA; MIHARA, CHIEKO; YANO, TETSUYA; KOZAKI, SHINYA;) 6 May 2004 (2004-05-06)
- D8: WO 2004/037889 A (CANON KK [JP]; FUKUI TATSUKI [JP]; YANO TETSUYA [JP]; MIHARA CHIEKO [J) 6 May 2004 (2004-05-06)
- D9: EP-A-1 340 777 (CANON KABUSHIKI KAISHA) 3 September 2003 (2003-09-03)
- D10: WO 2004/061530 A (CANON KABUSHIKI KAISHA; MIHARA, CHIEKO; YANO, TETSUYA; KOZAKI, SHINYA;) 22 July 2004 (2004-07-22)
- D11: WO 2004/061529 A (CANON KABUSHIKI KAISHA; FUKUI, TATSUKI; YANO, TETSUYA; MIHARA, CHIEKO;) 22 July 2004 (2004-07-22)
- D12: CAMMAS S ET AL: "Polymers of malic acid and 3-alkylmalic acid as synthetic PHAs in the design of biocompatible hydrolyzable devices" INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, BUTTERWORTH & CO., GUILDFORD, GB, vol. 25, 1999, pages 273-282, XP002339169 ISSN: 0141-8130
- D13: YAMAKOA T ET AL: "Synthesis and properties of malic acid-containing functional polymers" INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, BUTTERWORTH & CO., GUILDFORD, GB, vol. 25, 1999, pages 265-271, XP002339172 ISSN: 0141-8130
- D14: TROLLSAS M ET AL: "HYDROPHILIC ALIPHATIC POLYESTERS:
  DESIGN, SYNTHESIS, AND RING-OPENING POLYMERIZATION OF
  FUNCTIONAL CYCLIC ESTERS" MACROMOLECULES, AMERICAN
  CHEMICAL SOCIETY. EASTON, US, vol. 33, no. 13, 27 June 2000 (2000-

# WRITTEN OPINION OF THE INTERNATIONAL SEARCHING AUTHORITY (SEPARATE SHEET)

International application No.

PCT/JP2005/011001

06-27), pages 4619-4627, XP000950237 ISSN: 0024-9297

Cf V:

Article 33(2) PCT:

#### Claim 1:

None of the documents discloses the same combination of features as disclosed in **claim 1**.

Thus, the subject matter of claim 1 meets the requirements of Article 33(2) PCT.

The same remark applies also to claims 8,9 and 10.

#### Claim 5:

None of the documents discloses the same combination of features as disclosed in  ${f claim 5}$ 

Thus, the subject matter of claim 5 meets the requirements of Article 33(2) PCT.

#### Article 33(3) PCT:

**Document D7** represents the closest prior art. The difference **between D7** and **claim 5** is that **in claim 5**, the carboxylic acid (or salt thereof) is directly bonded to the polymer backbone whereas in D7, there is at least a methylene group between the carboxylic group and the polymer backbone. Since there are no comparative examples in accordance with D7, the objective technical problem is to provide further charge control agents based on functionalised PHA which have a good chargeability and a good stability with time.

Since in all the **documents D1 to D9**, there are no indications to specifically have a direct link between the carboxylic acid and the backbone in PHAs and since in **D12 to D14**, the polymers in accordance with formula (5) of claim 5 are used for medical applications, there are no indications to modify the formula of **compounds of D7**.

Thus, the subject matter of claim 5 meets the requirements of Article 33(3) PCT.

The same reasoning applies also to claim 1 (starting either from D7 or from D5).

Thus, the subject matter of claim 1 meets the requirements of Article 33(3) PCT.

The same remark applies also to claims 8,9 and 10.

#### Article 33(4) PCT:

The subject matter of all claims is capable of industrial applicability.

#### Cf VI:

### Published documents under Rule 70.10 PCT:

WO-A-2004/061530:

Publication date: 22.07.2004

Filing date: 26.12.2003 Priority date: 27.12.2002

WO-A-2004/061529

Publication date: 22.07.2004

Filing date: 26.12.2003 Priority date: 27.12.2002

#### Cf VII:

In page 50 (lines 6 to 10), n is not present in the formula (23).

In figure 7, the reference sign 41 is not explained and should be deleted. The same remark applies also to reference signs H, 6, and 10 in figure 1, 13, 15,16,18,A,B, and 17 in figure 2, and the reference signs in figures 5 and 6.

In tables 1 and 4, it is not clear if the results concerning the chargeability concern the toner or the corresponding double component.

#### Cf VIII:

#### **Article 6 PCT:**

In claims 1 and 5 the definition of the formula of the polyhydroxyalkanoate (PHA) is not clear since the specifications regrading  $I,m,Z_{1a},Z_{1b}$  and their equivalents in claim 5 are defined only by means of provisos. Thus, it is not clear what are the real ranges for I and m and the entire definition of  $Z_{1a}$ ,  $Z_{1b}$  and their equivalents in claim 5. Thus one cannot define the scope of protection of these claims.

Claims 2 to 4 and 6 to 7 are not supported by the description.